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The aims of the study were to determine whether symmetric dimethylarginine (SDMA) was increased in dogs with leishmaniosis
and to assess its relationship with creatinine concentration and urinary protein : creatinine ratio (UPC) to determine its utility as
a marker of early excretory dysfunction. Fifty-three dogs with leishmaniosis classified according to the LeishVet clinical staging
(stage I, 𝑛 = 5, stage II, 𝑛 = 30; stage III, 𝑛 = 12; stage IV, 𝑛 = 6) were selected and compared with 41 clinically healthy dogs.
Thirty-nine dogs with leishmaniosis were also followed up for six months. SDMA concentrations on the day of diagnosis were
significantly higher in dogs with leishmaniosis with respect to control dogs and in dogs from LeishVet stage IV when compared
with the other stages. Increased UPC (>0.5), SDMA (>19 𝜇g/dL), and creatinine concentrations (≥1.4mg/dL) were found in 47.1%,
15.1%, and 9.4% of dogs with leishmaniosis, respectively. SDMA concentration was increased in 24% of proteinuric dogs, in 7%
of nonproteinuric dogs, and in four of five dogs with increased creatinine. SDMA concentration ≥ 25 𝜇g/dL was associated with
clinical chronic kidney disease (CKD) after six months. Our results did not demonstrate advantages in using SDMA concentration
as an early marker of CKD when compared to creatinine and UPC in canine leishmaniosis.
1. Introduction
Canine leishmaniosis (CanL) is a widely distributed proto-
zoal disease that, in the Mediterranean basin, is caused by
Leishmania infantum and transmitted by phlebotomine sand
flies [1]. Infected dogs show a variable range of clinical mani-
festations depending on the type of immune response devel-
oped against the parasite [1–3]. Some dogs with predominant
cell mediated immunity may remain subclinically infected
[2], while those that develop a predominantly nonprotective
parasite specific humoral response tend to progress to clinical
illness [2, 4, 5].
Dogs with an exacerbated humoral response and hyper-
globulinemia can have deposition of circulating immune
complexes at the glomerular level, inducing inflamma-
tory changes that lead to glomerular damage [4, 6–8].
Histopathology of renal lesions in CanL commonly reveals
glomerulonephritis and tubulointerstitial nephritis [8, 9],
although some authors consider that tubulointerstitial lesions
appear secondarily to glomerular pathology due to inflamma-
tion and fibrosis of renal interstitium [10]. Initial glomeru-
lonephritis can manifest as asymptomatic proteinuria [8, 11],
but as the proteinuric nephropathy progresses, it can lead to
excretory dysfunction with increased or decreased glomeru-
lar filtration rate (GFR) [9, 12] and to systemic hypertension.
Increased GFR and hypertension can amplify the glomerular
pathology resulting in progression of chronic kidney disease
(CKD) [8]. Development of end stage CKD is a severe
manifestation of disease progression and the principal cause
of death in CanL [8, 13]. However, improvement of azotemia
and proteinuria depending on treatment and severity of
the disease has been described [9, 14, 15]. The two main
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parameters used to classify the degree of severity of renal
disease in dogs with leishmaniosis according to the LeishVet
clinical staging system are the urinary protein : creatinine
ratio (UPC) as a marker of glomerular pathology and crea-
tinine concentrations as a marker of excretory renal function
[16].
SDMA is a methylated arginine produced by cellular pro-
tein catabolism [17] that has demonstrated a good correlation
with creatinine and with GFR in dogs [18]. Several studies
have shown that SDMA is elevated in dogs with CKD [18, 19]
and with acute kidney injury [20]. Moreover, in CKD, SDMA
seems to increase earlier that creatinine [18, 19] and is not
influenced by dogs’ muscle mass [21], or inflammatory states
in humans [22, 23].
Recently, a new technique for the routine detection of
canine SDMA, namely, the IDEXX SDMA test, has been
developed and validated [24], and interpretation of SDMA
concentrations has been included in the International Renal
Interest Society (IRIS) CKD staging guidelines [25].
Since renal disease might develop in dogs with leish-
maniosis, feasible diagnostic tools, which might improve
the detection of decreased renal function, would be helpful
for the practicing veterinarian. Therefore, we proposed a
retrospective descriptive study with the following specific
objectives: (1) to determine serum SDMA concentrations
in dogs in different clinical stages of leishmaniosis [16] at
the time of diagnosis, (2) to evaluate the correlation of
SDMA concentrations with serum creatinine concentrations
and UPC, and (3) to describe the outcome of dogs with
leishmaniosis during six months after diagnosis.
2. Materials and Methods
2.1. Dogs and Serum Samples. Residual frozen serum samples
kept at −80∘C from 53 dogs with leishmaniosis and 41 healthy
age-matched dogs were used for this study.
Dogs had been diagnosed with leishmaniosis at five vet-
erinary centers from the northeast of Spain between January
2014 and December 2016. On the day of diagnosis, all dogs
had undergone physical examination and had laboratory tests
performed. The laboratory tests consisted of complete blood
cell count, biochemistry panel (with measurement of urea,
creatinine, cholesterol, alanine transaminase activity, and
total proteins concentrations), serumprotein electrophoresis,
an endpoint quantitative serology for the detection of L.
infantum specific antibodies by means of an ELISA in-house
[26], and a complete urinalysis with UPC determination.
Dogs with urinary infection and those without UPC per-
formed on the day of diagnosis were excluded from the study.
Diagnosis of leishmaniosis was based on compatible
clinical and clinicopathological findings along with high
serological antibodies levels or, in some cases, visualization
of the parasite in cytological samples from lymph node,
skin, or bone marrow. Occasionally, histopathological and
immunohistochemistry [27] identification ofLeishmania spp.
in cutaneous lesions was also performed.
According to the results of their physical examination
and laboratory tests, dogs were classified into the following
clinical stages: I (𝑛 = 5), II (𝑛 = 30), III (𝑛 = 12), and IV
(𝑛 = 6), as described by the LeishVet clinical staging system
[16] (Supplementary Table 1).
Healthy control dogs were owned by staff from several of
the veterinary centers involved in the study, or were brought
for routine health check or for sterilization. The inclusion
criteria for these dogs were (1) an unremarkable physical
examination, (2) a seronegative result by an in-house ELISA
for the detection of antibodies against L. infantum antigen
[26], and (3) no abnormalities in routine biochemistry or
hematological profile.
2.2. Follow-Up of Dogs with Leishmaniosis during Six Months.
Dogs with leishmaniosis had their medical records reviewed
to gather information about their clinical evolution during
the first six months following the diagnosis. Data about
their history, clinical signs, clinicopathological and serolog-
ical tests, urinalysis, UPC determination, and ultrasound
abnormalities were recorded. According to this information,
treated dogs were classified into two groups (Group A and
Group B) based on their clinical outcome and renal disease
status six months after diagnosis. Nontreated patients, dogs
that developed other diseases during the six months or had
insufficient tests performed to assess kidney function, were
excluded from the classification. Dogs with well-controlled
leishmaniosis that had no clinical signs or clinicopatho-
logical abnormalities suggesting CKD (including creatinine
concentration < 1.4mg/dL, UPC ≤ 0.5, adequate concen-
trating ability measured by refractometry, and absence of
renal abnormalities on physical examination or ultrasound
imaging) were assigned to Group A. Group B included dogs
with CKD as defined by IRIS staging guidelines [25] and dogs
that died during the follow-up period due to renal disease. An
algorithm showing how IRIS staging guidelines were applied
for the classification of dogs is shown in Figure 1.
2.3. SDMA, Creatinine, and UPC Analysis. UPC was mea-
sured on the day of diagnosis on urine samples with
inactive sediment. Urine samples collected by free catch
or cystocentesis were centrifuged and urinary protein was
measured using pyrogallol red combined with molybdate
(Beckman Coulter AU400) and urinary creatinine using
the Jaffe´ method (Beckman Coulter AU400). Dogs were
considered proteinuric when UPC was >0.5.
Banked serum samples were thawed and sent under
refrigeration to IDEXX Laboratories (Spain) for measure-
ment of SDMA and creatinine concentrations. SDMA con-
centration was measured using the IDEXX SDMA Test
(Beckman Coulter AU640) which is based on a previously
validated [24] immunoassay using a glucose-6-phosphate
dehydrogenase conjugate and an anti-SDMA monoclonal
antibody [28]. Creatinine concentration was measured using
the Jaffe´ method [29] (Beckman Coulter AU640). Creati-
nine concentrations ≥ 1.4mg/dL were considered increased
according to the IRIS and LeishVet classifications. Based on
IDEXX Laboratories algorithm for interpreting one-single-
point SDMA measurements [30], a medical decision cut-off
point of >19 𝜇g/dL was used to define increased concentra-
tions of SDMA.
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No evidence of CKD 
Although considered at risk due to previous
leishmaniosis or proteinuria
IRIS stage 1
If sustained inadequate concentrated
urine, sustained proteinuria or renal
mineralization
IRIS stage 2
If sustained inadequate concentrated urine,
sustained proteinuria or renal mineralization
IRIS stage 3: 
If sustained inadequate concentrated urine,
sustained proteinuria or renal mineralization
No
Yes
Creatinine
> 2–5∗ mg/dL
Creatinine
1.4–2∗ mg/dL
Creatinine
< 1.4∗ mg/dL
< 1.4∗ mg/dL
Creatinine
(i) Inadequate concentrating urine
ability of suspected kidney origin
(iii) Increase in serial blood creatinine
samples
(iv) Renal morphologic abnormalities
sustained UPC > 0.5–1.9
(ii) Renal proteinuria: UPC ≥ 2 or
Figure 1: Algorithm for classifying dogs with leishmaniosis after six months of diagnosis according to the presence of CKD based on IRIS
staging system [25]. IRIS: International Renal Interest Society; CKD: chronic kidney disease; UPC: urinary protein/creatinine ratio. ∗Blood
creatinine concentrations applied to average sized dogs. Values ≥ 1.4mg/dL were present more than once during the follow-up.
2.4. Statistical Analysis. Statistical analysis was performed
using a commercial software program (IBM SPSS Statistics
version 22). Parameters were investigated for normality using
the Kolmogorov-Smirnov test and data were analyzed using
nonparametric statistical methods. Correlation between cre-
atinine, SDMA, and UPC was measured using Spearman’s
correlation coefficient. Mann–Whitney 𝑈 test was used to
compare SDMA and creatinine concentrations, UPC, and
age between dogs with leishmaniosis and control dogs and
between Group A and Group B dogs, as well as SDMA
concentrations between proteinuric and nonproteinuric dogs
with leishmaniosis. SDMA concentration in dogs fromdiffer-
ent LeishVet stages was compared using the Kruskal-Wallis
test followed by a post hoc comparison with a Bonferroni
correction. Odds ratios and 95% confidence intervals for
dogs belonging to Groups A and B were calculated accord-
ing to the following cut-off values of several parameters
measured on the day of diagnosis: (1) SDMA concentration
> 19 𝜇g/dL and ≥25 𝜇g/dL, (2) creatinine concentration ≥
1.4mg/dL, and (3) UPC > 0.5 and >5 compared with lower
values. Fisher’s exact test was used to calculate 𝑝 values for
odds ratios. Significant differences were defined as having
𝑝 values < 0.05.
3. Results
3.1. Clinical Data at Diagnosis. Dogs with leishmaniosis
included 25 males (three neutered) and 28 females (13
spayed). Thirty-six of the 53 dogs were purebred. The main
breeds were distributed as follows: Boxer (𝑛 = 4), Labrador
Retriever (𝑛 = 2), and Greyhound (𝑛 = 2). In addition,
two dogs were from each of the following breeds: German
Shepherd, German Shorthaired Pointer, E´pagneul Breton,
Doberman, Golden Retriever, and French Bulldog. Sixteen
dogs from other different breeds were also included.
The healthy control group was composed of 20 males
(two neutered) and 21 females (four spayed). There were
three dogs of unknown breed, eleven mongrel dogs, four
Greyhounds, three Golden Retrievers, three Ibizan Hounds,
twoAriegeois, two Border Collies, two Teckels, two Pugs, two
English Setters, and seven other dogs, each from a different
breed.
Themedian age of dogswith leishmaniosiswas 48months
(range from 5 to 156 months), while the median age of
control dogs was also 48 months (from 6 to 132 months).
No significant differences in age were observed between both
groups (Mann–Whitney 𝑈 test; 𝑝 = 0.56).
SDMA concentration of dogs with leishmaniosis
(median = 13 𝜇g/dL, range = 8–42) was significantly higher
than that of control dogs (median = 11 𝜇g/dL, range 6–17)
(Mann–Whitney 𝑈 test, 𝑝 = 0.005). Figure 2 shows the
distribution of SDMA concentration in dogs with leishmani-
osis and control dogs. SDMA concentration was >19𝜇g/dL
in 8/53 (15.1%) dogs with leishmaniosis while all control
dogs were below this cut-off value. SDMA concentrations
were from 15 to 17 𝜇g/dL in seven control dogs. In addition,
SDMA concentrations were from 15 to 19𝜇g/dL in nine dogs
with leishmaniosis.
Five dogs with leishmaniosis (9.4%) had creatinine levels
≥ 1.4mg/dL (range 1.5–3.6). All of them were proteinuric,
and four of them had increased SDMA concentrations. The
dog with normal SDMA concentration (18 𝜇g/dL) was a
36-month-old Greyhound with creatinine concentration of
1.8mg/dL.
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Figure 2: Distribution of SDMA concentrations in 53 dogs with
leishmaniosis on the day of diagnosis (blue dots) and 41 control dogs
(red dots). The large black bar indicates the median of each group
and the whiskers indicate the interquartile range. The dashed line
indicates SDMA concentration of 19𝜇g/dL.
Dogs with leishmaniosis had median UPC of 0.4 (range
0.08–13.86), with 25/53 (47.1%) of them being proteinuric
(UPC > 0.5). SDMA concentrations were >19 𝜇g/dL (from 21
to 42𝜇g/dL) in 6/25 (24%) proteinuric dogs and in two
of 28 (7.1%) nonproteinuric dogs (with SDMA concentra-
tions of 22 𝜇g/dL and 30 𝜇g/dL). No significant differences
(Mann–Whitney 𝑈 test 𝑝 = 0.086) were found between
SDMA concentrations of nonproteinuric dogs (median
12 𝜇g/dL, range 8–30) with respect to proteinuric dogs
(median 14𝜇g/dL, range 8–42).
Four of the eight dogs with increased SDMA concentra-
tion were classified in LeishVet stage II; two of them were
not proteinuric and the other two had UPC between 0.5 and
1. One of the nonproteinuric dogs had SDMA concentration
of 30 𝜇g/dL, while the other three had SDMA concentrations
between 21 and 22𝜇g/dL. The other four dogs had SDMA ≥
25 𝜇g/dL. All of them were proteinuric and azotaemic and
were classified into stage III (𝑛 = 1) and stage IV (𝑛 = 3).
Figure 3 shows SDMA distribution in dogs from the different
LeishVet stages. No dogs in stage I had increased SDMA
concentrations. SDMA concentrations varied depending on
the LeishVet stage (Kruskal-Wallis 𝐻 test; 𝑋2(3) = 10.28,
𝑝 = 0.016). Post hoc analysis showed significant differences
between SDMA concentrations of stage IV when compared
with stage I (𝑝 = 0.02), stage II (𝑝 = 0.006), and stage
III (𝑝 = 0.004) dogs. There were no differences in SDMA
concentrations between the other stages.
SDMA concentration demonstrated a significant weak
positive correlation with creatinine concentration (Spear-
man’s rho = 0.386, 𝑝 < 0.0001) and no significant correlation
with UPC (rho = 0.243, 𝑝 = 0.080). UPC did not show
significant correlation with serum creatinine (rho = 0.056,
𝑝 = 0.693).
3.2. Six-Month Follow-Up. One nonazotaemic and nonpro-
teinuric dog with SDMA concentration of 30𝜇g/dL died
suddenly before starting treatment. Two dogs did not receive
treatment, and two other dogs were lost to follow-up before
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Figure 3: Distribution of SDMA concentrations in 53 dogs with
leishmaniosis on the day of diagnosis classified according to
LeishVet guidelines [16]. Stage I included 5 dogs, stage II 30 dogs,
stage III 12 dogs, and stage IV 6 dogs. SDMA concentration was
higher in dogs from stage IV with respect to stage I (𝑝 = 0.02), stage
II (𝑝 = 0.006), and stage III (𝑝 = 0.004) dogs. The large black bar
indicates the median of each group and the whiskers indicate the
interquartile range. The dashed line indicates SDMA concentration
of 19 𝜇g/dL.
the first month. The remaining dogs underwent treatment
with a daily subcutaneous injection of meglumine antimoni-
ate (80–100mg/kg) for amonth and allopurinol administered
orally (10mg/kg/12 hours) and were followed up for six
months.
Two of the four dogs with initial SDMA concentration
≥25 𝜇g/dL that received treatment died before the first month
due to CKD. The other two dogs were alive after six months
but presented CKD IRIS stage 2 and IRIS stage 3. The other
three dogs with increased SDMA (range 21-22𝜇g/dL) did not
show signs of CKD, and their SDMA normalized after six
months of follow-up. All these three dogs had been initially
classified as LeishVet stage II due to having UPC < 1. Figure 4
summarizes the clinical and renal outcomes of the 53 dogs
with leishmaniosis six months after diagnosis as well as their
classification in Group A and Group B.
Age, UPC, and creatinine and SDMA concentrations at
the time of diagnosis were compared between dogs from
Group A and Group B, finding significant differences in all
the parameters except for age (Table 1).
Table 2 shows the odds ratio for being classified in Group
A versus Group B after six months of diagnosis based on
different cut-off values of SDMA, creatinine, and UPC at
diagnosis.
4. Discussion
Studies regarding the use of SDMA as a renal biomarker for
kidney disease [18–20, 31–33] are sparse, and only one of them
included nonazotaemic dogs with leishmaniosis [33]. To the
best of the authors’ knowledge, this study assessed for the first
time SDMA concentrations in dogs with the four degrees of
disease severity established by the LeishVet clinical staging
system [16].
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Table 1: Comparison of age, creatinine, and SDMA concentrations and UPC on the day of diagnosis of leishmaniosis for Group A versus
Group B dogs.
Group A (median and range) Group B (median and range)
𝑝
𝑁 = 28 𝑁 = 11
Age (months) 42 (5–120) 62 (23–156) 0.14
Creatinine (mg/dL) 0.9 (0.7–1.3) 1.3 (0.8–3.6) 0.01
SDMA (𝜇g/dL) 12 (8–22) 17 (9–42) 0.018
UPC 0.28 (0.08–3.19) 4.15 (0.17–13.9) <0.0001
Group A: dogs with no evidence of renal disease based on the IRIS staging for CKD [25] after six months of diagnosis of leishmaniosis. Group B: dogs with
CKD classified as IRIS stage 1 to stage 3 and dogs euthanized or dead due to renal disease after six months of diagnosis of leishmaniosis. 𝑝: significance level
(Mann–Whitney 𝑈 test).𝑁: number of dogs; UPC: urinary protein/creatinine ratio.
Table 2: Odds ratio for being classified in Group A or Group B after six months of follow-up depending on several cut-off values of kidney
parameters on the day of diagnosis in 39 dogs with leishmaniosis.
Values on the day of diagnosis Odds ratio
∗ for being classified
in Group A
Odds ratio∗ for being classified
in Group B 𝑝
SDMA > 19 𝜇g/dL 0.21 (0.04–1.16) 4.76 (0.85–26.47) 0.074
SDMA ≥ 25 𝜇g/dL 0.03 (0.001–0.605) 34.2 (1.65–708.19) 0.022∗∗
UPC > 0.5 0.047 (0.005–0.429) 21.11 (2.33–191.17) 0.0067∗∗
UPC > 5 0.03 (0.001–0.605) 34.2 (1.65–708.19) 0.022∗∗
Creatinine ≥ 1.4mg/dL 0.021 (0.001–0.424) 48.23 (2.35–986.19) 0.00118∗∗
∗Expressed as odds ratio and its 95% confidence interval. ∗∗Significant value. Group A: dogs with no evidence of renal disease based on the IRIS staging for
CKD [25] after six months of diagnosis of leishmaniosis. Group B: dogs with CKD classified as IRIS stage 1 to stage 3 and dogs euthanized or dead due to renal
disease after six months of diagnosis of leishmaniosis. 𝑝: significance level (Mann–Whitney 𝑈 test). UPC: urinary protein/creatinine ratio.
Six months after
diagnosis
Dogs diagnosed
with leishmaniosis
(n = 53)
Classified based on their
renal status (n = 39)
GROUP B (n = 11):
Dead due to CKD (n = 3), IRIS stage
1 (n = 5), IRIS stage 2 (n = 2), IRIS
stage 3 (n = 1)
Dogs with no evidence of CKD
GROUP A (n = 28):
Non-classified based on their
renal status (n = 14)
Lost to follow up (n = 2)
Dead due to unrelated
diseases (n = 3) and unknown
causes (n = 1)
Insufficient tests performed
(n = 1)
Other diseases (n = 5)
Not treated (n = 2)
Figure 4: Flowchart depicting the clinical and renal outcome of 53 dogs with clinical leishmaniosis six months after diagnosis and their
classification into two groups according to the presence of CKD. Group A: dogs with no evidence of CKD six months after diagnosis. Group
B: dogs with CKD disease after six months of diagnosis or dogs that died due to renal disease during this period. Classification of IRIS stage
was done following the IRIS guidelines for staging CKD [25] as detailed in Figure 1. IRIS: International Renal Interest Society; CKD: chronic
kidney disease. 𝑛: number of dogs.
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Glomerulonephritis is the main pathological event in
leishmanial nephropathy [8], but severe glomerular pathol-
ogy can lead to a variable reduction of GFR [9, 12]. In
CanL, Plevraki et al. [9] found reduction of GFR in two
of ten asymptomatic nonazotaemic proteinuric dogs, and
Cortadellas et al. [12] in 11 of 26 dogs, most of them azotaemic
and highly proteinuric. We also detected more leishmaniotic
dogs with proteinuria (47.1%) than with increased SDMA
(15.1%) and creatinine (9.4%) concentrations, which are
markers of excretory dysfunction. The percentage of dogs
with increased SDMA in our study was lower in comparison
with these previous studies [9, 12], probably because of the
inclusion of a higher number of nonproteinuric dogs from
LeishVet stages I and II, which probably had no nephropathy
or a very low degree of it.We foundweak correlation between
serum creatinine and SDMA concentration, in agreement
with previous results in healthy dogs [21]. Creatinine and
SDMA are endogenous biomarkers of renal excretory func-
tion; however, SDMA has been suggested to increase earlier
than creatinine in CKD [18, 19]. In our study, we found
a Greyhound with a mild increase in creatinine without
elevated SDMA concentration. This result can be attributed
to the idiosyncrasy of this breed, which presents higher
creatinine concentrations [34] and probably SDMA levels
when compared with dogs from other breeds [35].
We did not find correlation between UPC and creatinine
or SDMA concentrations. The higher percentage of protein-
uric dogs in comparison with dogs with increased SDMA
or creatinine concentrations was expected as proteinuria
has been described as the first clinicopathological finding
indicating leishmanial nephropathy [8, 11], and not all dogs
with glomerulonephritis have damage severe enough to affect
excretory renal function. Besides, some proteinuric dogs can
develop glomerular hyperfiltration [12]which couldmaintain
normal SDMA concentration despite a higher degree of renal
pathology. Occasionally, the presence of proteinuria in the
absence of evident morphologic renal lesions has also been
observed in CanL [36], and it is hypothesized that overload
proteinuria due to serum excess of immunoglobulin free light
chain proteins could be present in these dogs. However, in the
present study, renal histopathology to confirm the absence of
kidney lesions or urine immunoelectrophoresis to determine
the origin of urinary proteins was not performed.
On the other hand, our study found two nonproteinuric
dogs with elevated SDMA concentration and creatinine
within reference limits. One of these dogs died unexpectedly
while the other one showed no clinical evidence of renal
disease after six months. Cortadellas et al. [12] found that one
of eight dogs with CanL and UPC levels between 0.2 and 0.5
had decreased GFR. Some dogs with leishmaniosis can have
an impairment of renal perfusion secondary to hypovolemia
or severe dehydration which would lead to an increase in
SDMA concentration not associated with proteinuria or
renal azotemia. Vasculitis of renal arterioles [37, 38] and
myocarditis [38–41] have also been described in dogs with
leishmaniosis and should be taken into account as less
probable causes of decreased GFR.We suggest that dogs with
leishmaniosis and moderate to high increases in SDMA con-
centrations without proteinuria should be carefully evaluated
for other diseases or pathogenic mechanisms which could
lead to prerenal impairment of renal perfusion.
We only found significant differences in SDMA concen-
trations in dogs from LeishVet stage IV with respect to the
other three stages. We did not find a higher percentage of
dogs with increased SDMA in stage III when compared with
stage II as would have been expected due to the progressive
increase in disease severity. Therefore, these results do not
support the use of SDMA concentration for a better classifi-
cation of severity in leishmaniosis, as dogs with stage IV have
azotaemia and/or UPC > 5.
The prognosis for dogs with leishmaniosis is highly
dependent on kidney function [16]. Improvement in kidney
parameters such as UPC and creatinine levels after treatment
has been described in dogs with leishmaniosis [9, 15]. In fact,
some of the dogs in our study with initial proteinuria and
increased SDMA did not show clinicopathological signs of
renal disease after six months. In the present study, high odds
ratios for presentingCKDor being dead after sixmonthswere
found for creatinine≥ 1.4mg/dL, SDMA≥ 25𝜇g/dL, andUPC
> 5. These cut-off values are probably associated with more
severe kidney disease and less reversible kidney damage. In
contrast, SDMA concentrations higher than 19𝜇g/dL were
not associated with an increased probability for presenting
CKD, probably reflecting a low degree of renal damage. All
dogs with initial SDMA concentration ≥ 25 𝜇g/dL died or
presentedCKD IRIS stage 2 or 3 after sixmonths of follow-up.
In agreement with the present results, SDMA concentrations
higher than 25 𝜇g/dL have been recommended by the IRIS
staging guidelines to classify dogs with low body condition
scores as IRIS stage 3 despite having creatinine concentrations
in the stage 2 range [25]. However, further studies with larger
numbers of dogs would be encouraged to determine if SDMA
concentration could be used as a prognosis marker for dogs
with leishmaniosis and other renal diseases.
Previous studies evaluating SDMA used the upper refer-
ence limit (URL) of 14 𝜇g/dL provided by IDEXX Laborato-
ries [18, 32, 33]. In our study, seven of 41 control dogs consid-
ered healthy had SDMA between 15 and 17 𝜇g/dL. For dogs
with no suspicion of renal disease, repeating single SDMA
measurement between 15 and 19 𝜇g/dL is recommended [30],
but this was not possible due to the retrospective nature of
our study. Some authors also have suggested that young dogs
and Greyhounds might have a URL higher than 14𝜇g/dL
[18, 36], and in a recent study [42], the mean SDMA
concentration of 20 apparently healthy dogs (12.7 𝜇g/dL) was
situated in the top quarter of the population-based reference
interval established by IDEXX Laboratories. Therefore, in
order to reduce the number of dogs with doubtful SDMA
classification (range 15–19 𝜇g/dL), we decided to use SDMA
>19 𝜇g/dL as a clinical decision cut-off value for both control
dogs and dogs with leishmaniosis to increase the specificity
of the test in spite of a decrease in sensitivity.
5. Conclusions
Based on the present study results, the use of SDMA in dogs
with leishmanial nephropathy has not shown advantages
in comparison with creatinine concentrations and UPC for
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predicting renal failure or for a better differentiation in
LeishVet stages. However, SDMA might be useful for detect-
ing excretory dysfunction in dogs with leishmaniosis by
other pathogenic mechanisms. Further studies investigating
SDMA concentrations in leishmaniosis and other diseases
with kidney involvement, as well as the association between
different cut-off values for medical decision limit of SDMA
and clinical outcome of dogs, are needed.
Data Availability
The datasets used during the current study are available from
the corresponding author on reasonable request.
Conflicts of Interest
Jaume Rodon is currently employed at IDEXX Laboratories,
Spain. The other authors declare that they have no conflicts
of interest.
Acknowledgments
This study was supported by a Spanish ministry grant
(AGL2012-32498, MINECO, FEDER, UE) and IDEXX Labo-
ratories. The authors thank all veterinarians and dog owners
that contributed to this study, especiallyMarta Blanchart (Ars
Veterinaria, Barcelona, Spain), Montsant Osso´ (Consultori
Falset, Tarragona, Spain), and Joan Llull (Mon Veterinari,
Manacor, Spain).The authors are also grateful to Dra. Lorena
Alborch, Dra. Pamela Martinez-Orellana, Daniel Mar´ı, and
Paulina Quirola (UAB) for their assistance with laboratory
work.
Supplementary Materials
A table titled “Supplementary Table 1” is included depicting
the criteria based on LeishVet staging guidelines that have
been used for the clinical staging of dogs with leishmaniosis
in this study. (Supplementary Materials)
References
[1] G. Baneth, A. F. Koutinas, L. Solano-Gallego, P. Bourdeau, and
L. Ferrer, “Canine leishmaniosis—new concepts and insights on
an expanding zoonosis: part one,”Trends in Parasitology, vol. 24,
no. 7, pp. 324–330, 2008.
[2] C. L. Barbie´ri, “Immunology of canine leishmaniasis,” Parasite
Immunology, vol. 28, no. 7, pp. 329–337, 2006.
[3] S. Hosein, D. P. Blake, and L. Solano-Gallego, “Insights on adap-
tive and innate immunity in canine leishmaniosis,”Parasitology,
vol. 144, no. 1, pp. 95–115, 2017.
[4] C. G. Nieto, M. Garc´ıa-Alonso, J. M. Requena et al., “Analysis of
the humoral immune response against total and recombinant
antigens of Leishmania infantum: Correlation with disease
progression in canine experimental leishmaniasis,” Veterinary
Immunology and Immunopathology, vol. 67, no. 2, pp. 117–130,
1999.
[5] E. Pinelli, R. Killick-Kendrick, J. Wagenaar, W. Bernadina, G.
Del Real, and J. Ruitenberg, “Cellular and humoral immune
responses in dogs experimentally and naturally infected with
Leishmania infantum,” Infection and Immunity, vol. 62, no. 1, pp.
229–235, 1994.
[6] A. Poli, F. Abramo, F. Mancianti, M. Nigro, S. Pieri, and A.
Bionda, “Renal involvement in canine leishmaniasis. A light-
microscopic, immunohistochemical and electron-microscopic
study,” Nephron, vol. 57, no. 4, pp. 444–452, 1991.
[7] L. Aresu, S. Benali, S. Ferro et al., “Light and Electron Micro-
scopic Analysis of Consecutive Renal Biopsy Specimens From
Leishmania-Seropositive Dogs,” Veterinary Pathology, vol. 50,
no. 5, pp. 753–760, 2013.
[8] A. F. Koutinas and C. K. Koutinas, “Pathologic mechanisms
underlying the clinical findings in canine Leishmaniosis due to
Leishmania infantum/chagasi,” Veterinary Pathology, vol. 51, no.
2, pp. 527–538, 2014.
[9] K. Plevraki, A. F. Koutinas, H. Kaldrymidou et al., “Effects of
allopurinol treatment on the progression of chronic nephritis
in canine leishmaniosis (Leishmania infantum),” Journal of
Veterinary Internal Medicine, vol. 20, no. 2, pp. 228–233, 2006.
[10] A. Zatelli, M. Borgarelli, R. Santilli et al., “Glomerular lesions in
dogs infected with Leishmania organisms,” American Journal of
Veterinary Research, vol. 64, no. 5, pp. 558–561, 2003.
[11] S. Paltrinieri, L. Gradoni, X. Roura, A. Zatelli, and E. Zini,
“Laboratory tests for diagnosing and monitoring canine leish-
maniasis,” Veterinary Clinical Pathology, vol. 45, no. 4, pp. 552–
578, 2016.
[12] O. Cortadellas, M. J. Ferna´ndez Del Palacio, J. Talavera, and A.
Bayo´n, “Glomerular filtration rate in dogs with leishmaniasis
and chronic kidney disease,” Journal of Veterinary Internal
Medicine, vol. 22, no. 2, pp. 293–300, 2008.
[13] P. Ciaramella, G.Oliva, R. de Luna et al., “A retrospective clinical
study of canine leishmaniasis in 150 dogs naturally infected by
Leishmania infantum,” Veterinary Record, vol. 141, no. 21, pp.
539–543, 1997.
[14] X. Roura, A. Fondati, G. Lubas et al., “Prognosis andmonitoring
of leishmaniasis in dogs: A working group report,” The Veteri-
nary Journal, vol. 198, no. 1, pp. 43–47, 2013.
[15] M. Pierantozzi, X. Roura, S. Paltrinieri, M. Poggi, and A. Zatelli,
“Variation of proteinuria in dogs with leishmaniasis treated
with meglumine antimoniate and allopurinol: a retrospective
study,” Journal of the American Animal Hospital Association, vol.
49, no. 4, pp. 231–236, 2013.
[16] L. Solano-Gallego, A. Koutinas, G. Miro´ et al., “Directions for
the diagnosis, clinical staging, treatment and prevention of
canine leishmaniosis,” Veterinary Parasitology, vol. 165, no. 1-2,
pp. 1–18, 2009.
[17] J. T. Kielstein, S. R. Salpeter, S. M. Bode-Boeger, J. P. Cooke, and
D. Fliser, “Symmetric dimethylarginine (SDMA) as endogenous
marker of renal function—ameta-analysis,”Nephrology Dialysis
Transplantation , vol. 21, no. 9, pp. 2446–2451, 2006.
[18] M. B. Nabity, G. E. Lees, M. M. Boggess et al., “Symmetric
dimethylarginine assay validation, stability, and evaluation as
a marker for the early detection of chronic kidney disease in
dogs,” Journal of Veterinary Internal Medicine, vol. 29, no. 4, pp.
1036–1044, 2015.
[19] J. A. Hall, M. Yerramilli, E. Obare, M. Yerramilli, K. Almes, and
D. E. Jewell, “Serum Concentrations of Symmetric Dimethy-
larginine and Creatinine in Dogs with Naturally Occur-
ring Chronic Kidney Disease,” Journal of Veterinary Internal
Medicine, vol. 30, no. 3, pp. 794–802, 2016.
[20] D. P. Dahlem, R. Neiger, A. Schweighauser et al., “Plasma
Symmetric Dimethylarginine Concentration in Dogs with
8 Veterinary Medicine International
Acute Kidney Injury and Chronic Kidney Disease,” Journal of
Veterinary Internal Medicine, vol. 31, no. 3, pp. 799–804, 2017.
[21] J. A.Hall,M.Yerramilli, E.Obare,M.Yerramilli, L.D.Melendez,
and D. E. Jewell, “Relationship between lean body mass and
serum renal biomarkers in healthy dogs,” Journal of Veterinary
Internal Medicine, vol. 29, no. 3, pp. 808–814, 2015.
[22] C. Zoccali, R. Maas, S. Cutrupi et al., “Asymmetric dimethyl-
arginine (ADMA) response to inflammation in acute infec-
tions,” Nephrology Dialysis Transplantation , vol. 22, no. 3, pp.
801–806, 2007.
[23] S. Blackwell, D. S. J. O’Reilly, D. Reid, and D. Talwar, “Plasma
dimethylarginines during the acute inflammatory response,”
European Journal of Clinical Investigation, vol. 41, no. 6, pp. 635–
641, 2011.
[24] P. Prusevich,D. Patch, E.Obare et al., “Validation of a novel high
throughput immunoassay for the quantitation of symmetric
dimethylarginine (SDMA),” Clinical Chemistry, vol. 61, no. S10,
p. S135, 2015.
[25] IRIS (International Renal Interest Society), “Staging of CKD
guidelines,” http://iris-kidney.com/pdf/003-5559.001-iris-web-
site-staging-of-ckd-pdf 220116-final.pdf.
[26] L. Solano-Gallego, L. Di Filippo, L. Ordeix et al., “Early reduc-
tion of Leishmania infantum-specific antibodies and blood
parasitemia during treatment in dogs with moderate or severe
disease,” Parasites & Vectors, vol. 9, no. 1, article no. 235, 2016.
[27] L. Ordeix, A. Dalmau, M. Osso, J. Llull, S. Montserrat-Sangra`,
and L. Solano-Gallego, “Histological and parasitological dis-
tinctive findings in clinically-lesioned and normal-looking skin
of dogs with different clinical stages of leishmaniosis,” Parasites
& Vectors, vol. 10, no. 1, article no. 121, 2017.
[28] D. Patch, E. Obare, P. Prusevich, H. Xie, and M. Yerramilli,
“High throughput immunoassay for kidney function biomarker
symmetric dimethylarginine (SDMA),” Clinical Chemistry, vol.
61, p. S135, 2015.
[29] C. Trumel, A. Dique´lou, H. Lefebvre, and J.-P. Braun, “Inac-
curacy of routine creatinine measurement in canine urine,”
Veterinary Clinical Pathology, vol. 33, no. 3, pp. 128–132, 2004.
[30] IDEXXLaboratories, “IDEXX SDMATest Algorithm,” https://
www.idexx.com/small-animal-health/products-and-services/
sdma-results-chart.html.
[31] J. A. Hokamp and M. B. Nabity, “Renal biomarkers in domestic
species,” Veterinary Clinical Pathology, vol. 45, no. 1, pp. 28–56,
2016.
[32] B.-S. Choi, H.-S. Moon, S.-H. Seo, and C. Hyun, “Evaluation
of serum cystatin-C and symmetric dimethylarginine concen-
trations in dogs with heart failure from chronic mitral valvular
insufficiency,” Journal of Veterinary Medical Science, vol. 79, no.
1, pp. 41–46, 2017.
[33] L. Pardo-Mar´ın, S.Mart´ınez-Subiela, J. Pastor et al., “Evaluation
of various biomarkers for kidney monitoring during canine
leishmaniosis treatment,” BMC Veterinary Research, vol. 13, no.
1, article no. 31, 2017.
[34] W. E. Feeman III, C. G. Couto, and T. L. Gray, “Serum creati-
nine concentrations in retired racing greyhounds,” Veterinary
Clinical Pathology, vol. 32, no. 1, pp. 40–42, 2003.
[35] J. Martinez, C. Kellogg, M. C. Iazbik et al., “The Renin-
Angiotensin-Aldosterone System in Greyhounds and Non-
Greyhound Dogs,” Journal of Veterinary Internal Medicine, vol.
31, no. 4, pp. 988–993, 2017.
[36] U. Bonfanti, E. Zini, E. Minetti, and A. Zatelli, “Free light-chain
proteinuria and normal renal histopathology and function in
11 dogs exposed to Leishmania infantum, Ehrlichia canis, and
Babesia canis,” Journal of Veterinary Internal Medicine, vol. 18,
no. 5, pp. 618–624, 2004.
[37] M. Pumarola, L. Brevik, J. Badiola, A. Vargas, M. Domingo,
and L. Ferrer, “Canine leishmaniasis associated with systemic
vasculitis in two dogs,” Journal of Comparative Pathology, vol.
105, no. 3, pp. 279–286, 1991.
[38] E. Torrent, M. Leiva, J. Segale´s et al., “Myocarditis and gener-
alised vasculitis associated with leishmaniosis in a dog,” Journal
of Small Animal Practice, vol. 46, no. 11, pp. 549–552, 2005.
[39] P. Silvestrini, M. Piviani, J. Alberola et al., “Serum cardiac
troponin I concentrations in dogs with leishmaniasis: Correla-
tion with age and clinicopathologic abnormalities,” Veterinary
Clinical Pathology, vol. 41, no. 4, pp. 568–574, 2012.
[40] F. A. Rosa, J. H. A. Leite, E. T. Braga et al., “Cardiac lesions in
30 dogs naturally infected with Leishmania infantum chagasi,”
Veterinary Pathology, vol. 51, no. 3, pp. 603–606, 2014.
[41] L. Mart´ınez-Herna´ndez, D. Casamian-Sorrosal, R. Barrera-
Chaco´n et al., “Comparison of myocardial damage among
dogs at different stages of clinical leishmaniasis and dogs with
idiopathic chronic kidney disease,”The Veterinary Journal, vol.
221, pp. 1–5, 2017.
[42] M. Kopke, R. Burchell, C. Ruaux, S. Burton, N. Lopez-
Villalobos, and A. Gal, “Variability of Symmetric Dimethylargi-
nine inApparentlyHealthyDogs,” Journal of Veterinary Internal
Medicine, vol. 32, no. 2, pp. 736–742, 2018.
